The Latest Research and Development Into the Antibody–Drug Conjugate, [Fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Chemical and Pharmaceutical Bulletin - Japan
doi 10.1248/cpb.c18-00744
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2019
Authors
Publisher
Pharmaceutical Society of Japan